About EnliTISA
EnliTISA’s vision is to improve the lives of patients with inflammatory and fibrotic diseases through the discovery and development of breakthrough therapies.
EnliTISA is a clinical stage biopharmaceutical company focused on developing novel therapeutics with a primary focus on inflammatory and fibrotic conditions with unmet medical needs.
EnliTISA, based in Shanghai, China, was founded by Chinese and Swedish team members in 2021, and is focusing on anti-inflammatory and anti-fibrosis multi-innovative drug development. The Chinese-Swedish team collaborates on pre-clinical and clinical development of drugs in China, Europe and the US.
All projects in the pipeline are based on the inventions made by the EnliTISA team. By now, twelve patent applications have been filed and two patents in China and one in US have been granted.
Founded in
International invention patents
Two projects are in clinical trial stage:
TISA-818, a new chemical entity, is intended to be used for the treatment of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS), and for Idiopathic Pulmonary Fibrosis (IPF).
A Phase I study in healthy volunteers conducted in China is expected to be completed by the end of 2022.
A Phase II study in patients with ARDS is planned to start in H1-2023 to start in May, 2023.
In H2-2023 the plan is to start a phase 1 trial in Europe.
Montelukast sodium topical sterile gel for anorectal surgery and radiation proctitis.
The rights to mainland China has been licensed to Shanghai Pharma.
A Phase I study in healthy volunteers has been completed. Phase II studies in the two indications are planning to start in H2-2023.
Ultimately, we aim to develop EnliTISA into a fully integrated pharmaceutical company by retaining commercial rights to our programs in China. For this purpose, we join forces with pharmaceutical companies in order to create strategic co-development alliances.
By now, three out-licensing deals of Chinese territory have been done with Shanghai Pharma. Four projects are planning for out-licensing in Europe, US and Asia, in 2023 and 2024.
Organizational
Our team
Co-founders
Bengt Ingemar Samuelsson
Nobel Prize winner, second largest shareholder, director of Shanghai company, chairman of Sweden subsidiary
· Rich accumulation of basic research on inflammation: 1982 Nobel Prize in Physiology or Medicine: Prostaglandins and related active substances · Rich experience in transformation of achievements: Originally developed montelukast sodium, celecoxib, Xlata, etc., and cooperated with Pfizer and Merck; served as director of 12 internationally renowned pharmaceutical companies and investment companies · Broad vision for basic research and industrial innovation: 12 years as dean of Karnarinska Institute in Sweden; 12 years as chairman of Nobel Foundation; nomination rights for Nobel Prize; Galen Award Jury
Jan-Christer Janson
Founding shareholder, director of Shanghai company, director of Sweden subsidiary
· Former Chief Scientist of Swedish Pharmacia Company · Protein and peptide purification and modification scientists · Winner of the International Science and Technology Cooperation Award of the People's Republic of China · Winner of Chinese Government Friendship Award
Gu Ming (Rainbow)
Founder, chairman and general manager
· Graduated from the State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences with a master's degree and a doctorate degree; won the National Science and Technology Major Scientific and Technological Achievement Award · Postdoctoral fellow and visiting scholar at Uppsala University, Sweden, under the tutelage of Prof. Jan-Christer Janson; visiting researcher at Uppsala University
Leadership Team
Gu Ming (Rainbow)
Founder, chairman and general manager
· Graduated from the State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences with a master's degree and a doctorate degree; won the National Science and Technology Major Scientific and Technological Achievement Award · Postdoctoral fellow and visiting scholar at Uppsala University, Sweden, under the tutelage of Prof. Jan-Christer Janson; visiting researcher at Uppsala University
Ru Hui
Ru Hui
Lars Öhman
Lars Öhman
Maria Wanderoy
Maria Wanderoy
Board members of EnliTISA Shanghai or Swedish daughter company
Bengt Ingemar Samuelsson
Nobel Prize winner, second largest shareholder, director of Shanghai company, chairman of Sweden subsidiary
· Rich accumulation of basic research on inflammation: 1982 Nobel Prize in Physiology or Medicine: Prostaglandins and related active substances · Rich experience in transformation of achievements: Originally developed montelukast sodium, celecoxib, Xlata, etc., and cooperated with Pfizer and Merck; served as director of 12 internationally renowned pharmaceutical companies and investment companies · Broad vision for basic research and industrial innovation: 12 years as dean of Karnarinska Institute in Sweden; 12 years as chairman of Nobel Foundation; nomination rights for Nobel Prize; Galen Award Jury
Jan-Christer Janson
Founding shareholder, director of Shanghai company, director of Sweden subsidiary
· Former Chief Scientist of Swedish Pharmacia Company · Protein and peptide purification and modification scientists · Winner of the International Science and Technology Cooperation Award of the People's Republic of China · Winner of Chinese Government Friendship Award
Jesper Zacharias Haeggstrom
Core member, director of Swedish subsidiary; Professor Samuelsson
· Focus on basic research on inflammation, including new target research; deeply cultivate the basis of arachidonic acid inflammation, and discover drug candidates from substances produced by the human body to fight inflammation and damage · Vice-Chairman of the Nobel Prize Review Committee for Medical Physiology
Gu Ming (Rainbow)
Founder, chairman and general manager
· Graduated from the State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences with a master's degree and a doctorate degree; won the National Science and Technology Major Scientific and Technological Achievement Award · Postdoctoral fellow and visiting scholar at Uppsala University, Sweden, under the tutelage of Prof. Jan-Christer Janson; visiting researcher at Uppsala University
Scientific affair & regulatory affair team
Anders Kärnell
Anders Kärnell
Anna Holmberg
Anna Holmberg
Jiang Taotao (Cathy)
Jiang Taotao (Cathy)
Anneli Hällgren
Anneli Hällgren
Alli Manninen
Alli Manninen
Kang Ruijuan (Alicia)
Kang Ruijuan (Alicia)
Xie Yue (Miya)
Xie Yue (Miya)
Maria Månsson
Maria Månsson
Sun Qingli
Sun Qingli
Jiao Feifei (Sarah)
Jiao Feifei (Sarah)
Christina Ståhl
Christina Ståhl
Gao Min (Amy)
Gao Min (Amy)
Lawyer
Stephen McNeeney:IP attorney
Potter Clarkson Intellectual Property Office, UK
· Has cooperated with the company for 5 and a half years, responsible for the company's intellectual property strategy construction and international PCT application, completed 12 international invention patent applications, 2 Chinese patent authorizations, and 1 US patent authorization. IP due diligence and negotiation to support Chinese and overseas transactions · Supported over 70 clients in IP due diligence and negotiation of intercontinental licensing transactions
Patti Kavee Melick:BD lawyer
Commercial Lawyer for Pharmaceutical License Transactions, WIGGIN AND DANA Law Firm, USA
· Over 20 years of cooperation with Lars Öhman, the company's senior commercial leader, on other company project transactions. Support business negotiation and contract review of overseas transactions · Extensive experience in intercontinental licensing transactions, including licensing applications for Chinese and US pharmaceutical companies
Huang Kujuan: BD lawyer
Huang Kujuan: BD lawyer
Sun Yu: IPO affairs
Sun Yu: IPO affairs
Culture
Enlitisa
Corporate Mission
To be an original research and innovation drug enterprise with strong vitality and fighting power
Corporate Vision
To be an original research and innovation drug enterprise with strong vitality and fighting power, and repay the support of shareholders, society and the government with good drugs and taxes that can withstand the years
Honor
Tel:+86-021-33758853
Add:Room 201, 202, 203, BuildingA, Block1, No. 800, Qingdai Road, Pudong New District, Shanghai
Copyright ©2022 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | SEO 沪ICP备2022023966号-1 Powered by www.300.cn